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Context: Rapidly increasing evidence has documented that endocrine-disrupting chemicals (EDCs)
contribute substantially to disease and disability.
Objective: The objective was to quantify a range of health and economic costs that can be reasonably
attributed to EDC exposures in the European Union (EU).
Design:ASteeringCommitteeofscientistsadaptedtheIntergovernmentalPanelonClimateChangeweight-
of-evidence characterization for probability of causationbasedupon levels of available epidemiological and
toxicological evidence for one or more chemicals contributing to disease by an endocrine disruptor mecha-
nism. To evaluate the epidemiological evidence, the Steering Committee adapted the World Health Orga-
nization Grading of Recommendations Assessment, Development and Evaluation (GRADE)Working Group
criteria, whereas the Steering Committee adapted definitions recently promulgated by the Danish Environ-
mental Protection Agency for evaluating laboratory and animal evidence of endocrine disruption. Expert
panels used the Delphi method to make decisions on the strength of the data.
Results: Expert panels achieved consensus at least for probable (20%) EDC causation for IQ loss and
associated intellectual disability, autism, attention-deficit hyperactivity disorder, childhood obesity, adult
obesity, adult diabetes, cryptorchidism,male infertility, andmortality associatedwith reduced testosterone.
Accounting for probability of causation and using the midpoint of each range for probability of causation,
Monte Carlo simulations produced amedian cost of€157 billion (or $209 billion, corresponding to 1.23%of
EUgrossdomesticproduct)annuallyacross1000simulations.Notably,usingthe lowestendof theprobability
range for each relationship in the Monte Carlo simulations produced a median range of €109 billion that
differed modestly from base case probability inputs.
Conclusions: EDCexposures in theEUare likely to contribute substantially todiseaseanddysfunctionacross
the life course with costs in the hundreds of billions of Euros per year. These estimates represent only those
EDCswith thehighest probability of causation; abroader analysiswouldhaveproducedgreater estimates of
burden of disease and costs. (J Clin Endocrinol Metab 100: 1245–1255, 2015)
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TheEuropeanUnion (EU)defines an endocrine-disrupt-ing chemical (EDC) as an “exogenous substance that
causes adverse health effects in an intact organism, or its
progeny, secondary to changes in endocrine function” (1–
3). EDCs are diverse in their chemical structure, but all
known EDCs interfere with hormone action to cause ad-
verse effects, resulting in increased incidence of disease/
dysfunction (3). For example, the water contaminant per-
chlorate is an EDC because it directly inhibits thyroid
hormone synthesis, restricting the availability of thyroid
hormone in target tissues, thereby interfering with thy-
roid hormone action (eg, Ref. 4), whereas bisphenol A
(BPA) is an EDC in part because it can act through the
estrogen-related receptor- to alter insulinproductionand
release, thus contributing to the pathogenesis of insulin
resistance and type 2 diabetes (5).
The past 20 years have produced a great deal of new
information from experimental studies focused onmolec-
ular, cellular, and animal experiments to epidemiological
studies demonstrating that awide array of chemical struc-
tures—pharmaceuticals, personal care products, commer-
cial chemicals, and environmental pollutants—can interfere
with hormone action (6). Among the chemicals known to
be EDCs are diethylstilbestrol (7), polychlorinated biphe-
nyls, dioxins, perfluoroalkyl compounds, solvents, phtha-
lates (8), BPA (9), dichlorodiphenyldichloroethylene
(DDE) (10), organophosphate and organochlorine pesti-
cides (11), and polybrominated diphenyl ethers (PBDEs)
(12, 13). These chemicals have been shown to interfere
with a variety of endocrine pathways, including estrogen
(14), androgen (14), thyroid (15, 16), retinol (17), aryl
hydrocarbon, and peroxisome proliferator-activated re-
ceptor pathways (18). The chemicals are widely used in
consumer products, electronics, and agriculture, and
widespreadhuman exposures occur.ManyEDCsare food
contaminants (eg, pesticides, BPA, and phthalates), al-
though inhalation and dermal absorption are known
pathways for human exposure. Potential consequences of
exposure to EDCs include infertility and male and female
reproductivedysfunctions (19), prostate andbreast cancer
(20), birth defects (21), obesity (22, 23), diabetes, cardio-
pulmonary disease, neurobehavioral and learning dys-
functions, and immune dysregulation (24). Laboratory
data on these associations are supplemented by varying
levels of epidemiological evidence for each chemical-dis-
ease/dysfunction dyad. In part due to uncertainty of cau-
sation, no estimate of the health or economic burden of
EDCs has been made. Systematic estimates of burden of
disease attributable to EDC exposures could help inform
decision-making that protects public health.
The EU is taking the lead on regulating EDCs, through
legislation such asREACH (Registration, Evaluation, Au-
thorization and Restriction of Chemicals) and regulations
on pesticides and biocides (25). The outcome of these pol-
icy discussions will be crucial not only for consumer and
public health protection in the EU, but also for setting
scientific and regulatory policy precedents for other na-
tional policies including those consistent with implemen-
tation of global agreements such as SAICM (the Strategic
Approach to International ChemicalsManagement) (26).
A critical element in the regulation of EDCs in EU policy
will be the criteria by which test outcomes for EDCs are
translated into regulatory action. These criteria will de-
termine, based on the functional properties of each chem-
ical and responses measured in appropriate test systems,
whether it will be restricted, phased out, or allowed to
enter or remain on the EU market. The EU Commission
has requested that an impact assessment be conducted to
assess the economic implications of the criteria under dis-
cussion (27). The impact assessment is focused on the eco-
nomic impact to industry of regulating EDCs in Europe.
Our goal here is to estimate the health and economic ben-
efit of regulating EDCs in Europe, based on current
evidence.
We now describe the general methods used to attribute
disease and disability to EDCs, toweigh the probability of
causation based upon the available evidence, and to trans-
late attributable disease burden into costs. During a 2-day
workshop in April 2014, five expert panels identified con-
ditions where the evidence is strongest for causation and
developed ranges for fractions of disease burden that can
be attributed to EDCs. Although accompanying manu-
scripts describe in greater detail the bases for their esti-
mates of disease attribution and probability of causation,
we present here an overview of the methods they applied
as well as approaches applied to estimate disease burden
and costs attributable to EDCs in the EUbased upon those
data inputs.
Materials and Methods
General approach
In 1981, the Institute of Medicine developed a general ap-
proach to assess the “fractional contribution” of the environ-
ment to causation of illness in the United States, which remains
widely used to this day and is depicted in Equations 1 and 2 (28):
Attributable disease burdenDisease rate
 Attributable fraction (AF) Population size (1)
Attributable CostsDisease rate AF Population size
 Cost per case (2)
where “cost per case” refers to discounted lifetime expenditures
attributable to a particular disease, including direct costs of
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health care, costs of rehabilitation, and lost productivity; disease
rate and population size refer, respectively, to either the inci-
dence or prevalence of a disease and the size of the population at
risk. AF is defined by Smith et al (29) in the context of environ-
mental health as “the percentage of a particular disease category
that would be eliminated if environmental risk factors were re-
duced to their lowest feasible concentrations.” The AF is a com-
posite value and represents the product of the prevalence of a risk
factor multiplied by the relative risk of disease associated with
that risk factor (30); it is estimated using the following equation:
AF Prevalenceexposure * (RR 1)
/1 (Prevalenceexposure * (RR 1)), (3)
where RR is the relative risk of morbidity associated with the
exposure. An alternative formulation of Equation 1 would pre-
suppose an exposure-outcome relationship that would result in
discrete calculations of the increment in disease or disability over
and above a comparison, unexposed group, and is presented in
the following equation:
Disease burden Incremental prevalence or incidence
 Population (4)
Accounting for uncertainty and probability
of causation
In the past, certainty of causation, however defined, has been
presumed to be a requirement before pursuing estimates of at-
tributable disease burden or costs, when in reality causation is
not simply binary. In his widely cited work about the criteria for
causation, SirAustinBradfordHill acknowledged the reality that
“all scientific work is incomplete—where it be observational or
experimental,” noting that uncertainty “does not confer upon us
a freedom to ignore the knowledge we already have, or to post-
pone the action that it appears to demand at a given time” (31).
The Intergovernmental Panel on Climate Change (IPCC) has
managed uncertainty by applying a weight-of-evidence charac-
terization for probability of causation (32). A Steering Commit-
tee of scientists overseeing the project (M.B., J.D., P.G., J.J.H.,
A.K., J.P.M., L.T., R.T.Z.) adapted the IPCC approach to as-
sessing probability of causation based upon the available epide-
miological and toxicological evidence for one or a group of
chemicals contributing to disease by an endocrine disruptor
mechanism. The schema is presented in Table 1, and subsequent
paragraphsdelineate theapproach toevaluating epidemiological
and toxicological evidence.
To evaluate the epidemiological evidence, theGRADEWork-
ing Group criteria (33, 34) were adapted as they were recently
applied in evaluating indoor air quality criteria by the World
Health Organization (35). As described in Table 2, the criteria
utilize study designs as a primary basis for distinguishing
strength of evidence, with factors specific to the studies (both
individually and in the aggregate) such as potential bias, limita-
tions, strength of dose-response relationships, residual con-
founding, consistency, and analogy permitting upward and
downward grading of the quality of evidence.
To evaluate the toxicological evidence, the Steering Commit-
tee adapted criteria recently promulgated by the Danish Envi-
ronmental Protection Agency for evaluating laboratory and an-
imal evidence of endocrine disruption (36). The schema is
presented in Table 3. Identification of an endocrine mechanism/
mode of action and corroboration of toxicity in laboratory
model studies was required to assess the toxicological evidence
for the exposure-outcome association as group 1 (endocrine dis-
ruptor). Group 2A (suspected endocrine disruptor) required ei-
ther: 1) the presence of an endocrine disruptor mode of action
without clear corroboration of themode of action producing the
expected adverse effects in laboratory or animal studies; or 2) the
presence of the adverse effects in laboratory animal studies with
a suspected endocrine mode of action. Exposure-outcome asso-
ciations were evaluated to have group 2B (potential endocrine
disruptor) toxicological evidence when there was evidence of
adverse effects in animal studies that could have either an endo-
crine mode of action or a nonendocrine mode of action or in
vitro/in silico evidence indicating a potential for endocrine dis-
ruption in intact organisms.
Quantifying attributable burden
The Steering Committee noted three general approaches on
which to base attribution to EDCs: 1) trends in incidence/prev-
alence over and above a baseline that would be difficult to at-
tribute to genetics accompanied by information on likely causal
mechanisms by EDCs and/or increasing exposure; 2) data from
genetic studies that permit quantification of the remaining en-
vironmental contribution (within which onemight posit EDC to
contribute a portion); and 3) dose-response relationships from
the epidemiological literature. In general, the Steering Commit-
tee prioritized the third approach. In the absence of epidemio-
logical evidence for a dose-response relationship, the presence of
toxicological data documenting effect and mechanism and/or
other data might suggest a strong basis from which to reason an
incremental effect in humans. In this scenario, the first two lines
of evidence would add support to an estimate of the degree that
one or more EDCs might contribute to the condition under
consideration.
Although chemicals banned by Europe (eg, under the Stock-
holm Convention) have been documented to be endocrine dis-
ruptors and contribute to disease and disability, panels were
Table 1. Framework for Evaluating Probability of Causation
Epidemiological
Evaluation
Toxicological Evaluation
Strong (Group 1) Moderate (Group 2A) Weak (Group 2B)
High Very High (90–100%) High (70–89%) Medium (40–69%)
Moderate High (70–89%) Medium (40–69%) Low (20–39%)
Low Medium (40–69%) Low (20–39%) Very Low (0–19%)
Very Low Low (20–39%) Very Low (0–19%) Very Low (0–19%)
Adapted from Ref. 32.
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advised not to examine effects of these exposures unless there
was a compelling case that interventions outside Europe could
influence disease and disability in Europe. For example, the obe-
sity panel did not quantify the obesogenic and diabetogenic ef-
fects of other EDCs that continue to contaminate the EU general
population (eg, polychlorinated biphenyls and hexachloroben-
zene) because they are banned under the Stockholm Convention
(37, 38). In contrast, DDE-attributable obesity and diabetes
could be prevented through further reductions in dichlorodiphe-
nyltrichloroethane use globally, which is substantially relevant
due to the current use of this chemical formalaria control and its
long-range transport and persistence in the environment (39).
Panels were advised to consider all possible developmental
windows of vulnerability, but to focus on exposure timing and
duration, with the strongest evidence for causation from toxi-
cological and epidemiological data. When a dose-response rela-
tionship was identified for a particular exposure period, this
relationship was applied to the EU population based upon bio-
marker data available from large surveys or pooled data from
multiple studies in individual countries. Biomarkers were then
estimated for quantiles (usually 0-ninth, 10–24th, 25–49th, 50–
74th, 75–89th, 90–99th) in recognition that narrower quantiles
might reduce precisionof estimates. In the rare circumstance that
there were no epidemiological studies on which to assess a dose-
response relationship, but there existed enough evidence to sug-
gest an effect in a portion of the appropriate population, a rel-
ative risk was estimated, and a prevalence of exposure was
identified to estimate an attributable fraction, using Equation 3.
Whenever possible, the most population-representative data
were used for appropriate exposure and/or biomarker inputs
because convenience samples may have unmeasurable biases re-
sulting in misestimation of exposure, and these inputs were ap-
plied consistently across all the exposure-outcome associations
studied.
Approach to evaluating evidence
Following the World Health Organization/United Nations
Environment Programme State of the Science of Endocrine Dis-
rupting Chemicals, which identified three distinct sets of health
endpoints with the most substantial evidence for EDC attribu-
tion (obesity/diabetes, male reproductive health, and neurode-
velopmental disability) (24), the Steering Committee convened
expert panels for each of the domains composed of four to eight
scientific experts. Two expert panels were also convened for
breast cancer and female reproductive conditions; their deliber-
ations are following an identical process to that described below,
are nearing completion, and will be the basis for future reports.
The Steering Committee identified epidemiological and toxico-
logical experts, based upon their scholarly contribution in the
diseases under consideration and endocrine disruptor toxicol-
ogy, and invited them to attend a 2-day scientific meeting in
Paris, which was held at the French National Alliance for Life
Sciences and Health from April 28–29, 2014.
Table 2. Criteria for Evaluating Epidemiological Evidence
Quality of
Evidence Interpretation Study Design
Lower Quality
in Presence of:
Raise Quality in
Presence of:
High We are very confident that
the true effect lies close to
that of the estimate of the
effect
Randomized trial Study limitations:
1 Serious
limitations
Strong association: 1
Strong, no plausible
confounders, consistent
and direct evidence
Moderate We are moderately confident
in the effect estimate: The
true effect is likely to be
close to the estimate of
the effect, but there is a
possibility that it is
substantially different
Quasi-experimental (with
controls) and before
and after
(uncontrolled) studies
2 Very serious 2 Very strong, no major
threats to validity and
direct evidence
Limitations 1 Evidence of a dose-
response gradient
1 Important
inconsistency
1 All plausible
confounders would
have reduced effect
Low Our confidence in the effect
estimate is limited: The
true effect may be
substantially different from
the estimate of the effect
Observational study Directness: 1
Some
uncertainty
2 Major
uncertainty
Additional criteria (applied
across a body of
evidence based on
multiple study designs):
1 Imprecise
data
1 Consistency across
multiple studies in
different settings
Very low We have very little
confidence in the effect
estimate: The true effect is
likely to be substantially
different from the estimate
of effect
Any other evidence 1 High
probability of
reporting bias
1 Analogy across other
exposure sources
Adapted from Refs. 33 and 75.
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During this meeting, the Steering Committee applied a mod-
ified Delphi approach (40) to evaluating the strength of the ep-
idemiological and toxicological evidence and the nature of the
association between exposures and outcomes. The Delphi
method was developed on the premise that group judgments are
more valid than those of individuals. Although named after the
oracle at the sanctuarydedicated toApollo in the5th centuryBC,
the method is not mystical and was first developed at the begin-
ning of the Cold War to forecast technological impacts on war-
fare (41). Helmer, Dalkey, and Rescher at the RAND Corpora-
tion formalized the method in the 1950s for science and
technology forecasting (42). It has been applied successfully and
with high consistency and rigor across many disciplines includ-
ing health and education (43–46).
Teleconferences with participants were held biweekly over a
3-month period to encourage familiarity with literature being re-
viewed, to describe the Delphi method (including the definition of
terminology and interaction structure) (41), and to identify group
leaders (P.G., R.H., and J.L.). An initial presentation at the begin-
ning of the 2-daymeeting provided an overview of the process and
further clarified the definition of EDC to be used. The Endocrine
Society defines EDCs, somewhat differently than the EU, as an ex-
ogenous chemical or mixture of chemicals that can interfere with
any aspect of hormone action (3). Because of the EUdecision-mak-
ing context, panelists were advised to adhere to the EU definition
but to add a further requirement that the chemicals interfere with
hormoneaction(aselaborated inTheEndocrineSocietydefinition).
Panels began by selecting the association for which the evi-
dence was judged to be the strongest to promote familiarity in
subsequent iterations. For each exposure-outcome association,
the process in each group began with the presentation of ep-
idemiological and toxicological reviews of the literature and
a discussion of the approach to identifying the overarching
issues in attributing individual EDC exposures to the subject
outcome. Expert panelists were then asked to provide their
opinions about the strength of the epidemiological and toxi-
cological evidence for the exposure-outcome relationship and
the nature of that relationship. Responses were submitted to
the leader anonymously.
Each leader then provided a summary of the findings from
initial questionnaires and reasons for the judgments. Panelists
were encouraged to refine their answers anonymously in light of
replies of other experts on the panel, with a goal of convergence
towarda consensus in subsequent roundsofquestionnaires. Pan-
elists were advised to consider the Smith et al (29) definition of
AF, ie, “the percentage of a particular disease category that
would be eliminated if environmental risk factors were reduced
to their lowest feasible concentrations.” Recognizing that natu-
rally occurring EDCs such as phytoestrogens do exist in the en-
vironment, the Steering Committee encouraged estimation of
AFs attributable to anthropogenic activities, recognizing that
naturally occurring exposures (eg, phytoestrogen exposure from
soymilk)may also contribute (47). Panelists were asked to focus
on EU populations, identifying the population affected (includ-
ing age and demographic subgroups) as part of their iterative
process, in addition to the population in which the outcome is
being assessed. They were asked to consider the reality of mix-
tures and complexity of attribution in that context.
Table 3. Criteria for Evaluating Toxicological Evidence
Quality of
Evidence Interpretation Study Design
Strong, group 1
(endocrine
disruptor)
There is a strong presumption
that the chemical has the
capacity to cause the health
effect through an
endocrine disruptor
mechanism.
The animal studies provide clear evidence of the ED effect in the absence
of other toxic effects, or if occurring together with other toxic
effects, the ED effects should not be a secondary nonspecific
consequence of other toxic effects. However, when there is, eg,
mechanistic information that raises doubt about the relevance of the
effect for humans or the environment, group 2 may be more
appropriate.
Substances can be allocated to this group based on:
Adverse in vivo effects where an ED mode of action is plausible
ED mode of action in vivo that is clearly linked to adverse in vivo
effects (eg, by read across)
Moderate, group 2a
(suspected
endocrine
disruptor)
There is some evidence from
experimental animals, yet
the evidence is not
sufficiently convincing to
place the substance in
group 1.
The health effects are observed in the absence of other toxic effects, or if
occurring together with other toxic effects, the ED effect should be
considered not to be a secondary nonspecific consequence of other
toxic effects.
Substances can be allocated to this group based on:
Adverse effects in vivo where an ED mode of action is suspected
ED mode of action in vivo that is suspected to be linked to adverse
effects in vivo
ED mode of action in vitro combined with toxicokinetic in vivo
data (and relevant non-test information such as read across,
chemical categorization, and QSAR predictions)
Weak, group 2b
(potential
endocrine
disruptor)
There is some evidence
indicating potential for
endocrine disruption in
intact organisms.
There is some in vitro/in silico evidence indicating a potential for
endocrine disruption in intact organisms or effects in vivo that may,
or may not, be ED-mediated.
Abbreviations: ED, endocrine disruptor; QSAR, quantitative structure–activity relationship. Adapted from Ref. 36.
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Management of ongoing discussions and triggers of subse-
quent rounds of questionnaires were determined by the expert
panel leaders. Consistent with application of the Delphi method
to aspects of medical care (45, 46, 48), predefined stop criteria
included: a minimum of three questionnaire rounds, achieve-
ment of majority consensus, and stability of results across
rounds. Converging answers for each EDC-outcome relation-
ship formed the basis for manuscripts accompanying this over-
view, which describe each expert panel process and were pre-
pared by the expert panel leads in collaboration with the other
members after the meeting. Throughout the Delphi process, the
panels were strongly encouraged to produce ranges that repre-
sent low and high bounds for the dose-response relationship and
to evaluate potential nonlinearity and nonmonotonicity as well
as the presence or absence of threshold effectswhen appropriate.
Nonmonotonicity did not influence strength of evidence when
supported in its biological plausibility, although it could yield
differences in the estimateddiseaseburden.While unanimitywas
encouraged, in the event of nonunanimity, the range of strength
of evidence evaluations from all participants was input to de-
velop a range of results for probability of causation.
General approach to economic estimation
We applied a human capital approach (49, 50), which is cur-
rently the most widely used method to calculate the costs of
illness (51, 52). This approach measures the value of resources
foregone and output lost due to illness, such as lost earnings or
household contributions as a homemaker, and costs of medical
treatment. With this method, costs were divided into direct and
indirect costs. In calculating these costs, we followed the widely
cited costing guidelines recommended by the Panel on Cost Ef-
fectiveness and Medicine (53). Direct costs are the value of re-
sources that could be allocated to other uses in the absence of
disease. These include expenditures for hospitalization, physi-
cian services, nursing home care,medical appliances, and related
items. Indirect costs are the value of the lost output of workers
and retirees suffering premature death or disability.We assumed
the societal perspective, as opposed to the perspective of the
health care payer (54), and our measures of costs adhered as
closely as possible to the economic definition of costs, where cost
is represented by foregone opportunities.
Whenever possible, we utilized European data sources for
cost-of-illness inputs and relied upon already published esti-
mates when available. Our preference was to identify incremen-
tal costs associated with a condition, rather than average costs,
because these tend to produce overestimates (55). When Euro-
pean datawere not available, we extrapolated from available US
estimates, applying a correction factor representing the ratio of
the per capita gross domestic product (GDP) purchasing power
parity of each European country compared to the United States.
All results are presented in 2010 Euros, and represent costs as
estimated to occur in 2010, the most recent year for which prev-
alence/incidence data could permit robust estimation.
Finally, recognizing that attributable cost estimates were ac-
companied by a probability, we performed a series of Monte
Carlo simulations to produce ranges of probable costs across all
the exposure-outcome relationships, assuming independence of
each probabilistic event. Separate random number generation
events were used to assign 1) causation or not causation, and 2)
cost given causation, using the base case estimate as well as the
range of sensitivity analytic inputs produced by the expert panel.
To illustrate with an example, for an exposure-outcome rela-
tionship with an 80% probability of causation, random values
between 0 and 1 in each simulation led to the first step, which
either assigned no costs (randomvalue 0.2) and costs (random
value  0.2). For relationships in which lower and/or higher
bound estimates of costs were identified in addition to base case
costs, a second random number generation was used to assign
costs in the scenario of causation. For those relationships with a
lower and outer bound estimate, equal probabilities were as-
signed to values below and above the base case estimate, with
costs linearly interpolated across the remaining probability
range. For relationships for which only a higher or lower bound
estimate was available, a 50% probability was assigned for the
base case estimate, whereas the remaining 50% probability was
applied over the range of the higher/lower bound.
Recognizing that probability of causation could be highly
influential on cost estimates, we performed three sets of 1000
simulations, using the midpoints of the ranges for probability of
causation for each exposure-outcome relationship as a base case
scenario and low and high bounds of the probability range as
alternate scenarios to assess the sensitivity of Monte Carlo sim-
ulations to this input. For eachof the three sets of simulations,we
produced ranges of burden and disease costs associated with
EDCs. We developed a 95% confidence interval as well as the
interquartile range and first and ninth deciles to convey the
spread of possible scenarios.
Results
Expert panels achieved consensus at least for probable
(20%) EDC causation for IQ loss and associated intel-
lectual disability, autism, attention deficit hyperactivity
disorder, childhood obesity, adult obesity, adult diabetes,
cryptorchidism, male infertility, and mortality associated
with reduced T (Table 4). Only for testicular cancer was
0–19% probability of causation identified. We refer the
reader toaccompanyingmanuscripts thatdescribe specific
results from each of the expert panels (56–58), but to
illustrate we present burden of disease results from a few
examples here.
The neurodevelopment panel estimated a strong prob-
ability (70–100%) that each year in Europe, 13.0 million
IQ points are lost (sensitivity analysis, 4.24–17.1 million)
due to prenatal organophosphate exposure, and 59 300
additional cases of intellectual disability (sensitivity anal-
ysis, 16 500 to 84 400). With more modest probabilities,
316 cases of autism (sensitivity analysis, 126–631) and
19 400 to 31 200 new cases of attention-deficit hyperac-
tivity disorder annually are attributable to EDCs. The
male reproductive panel identified male infertility attrib-
utable to phthalate exposure to have a 40–69% proba-
bility of causing 618 000 additional assisted reproductive
technology procedures annually in Europe. A 40–69%
probability of lower T concentrations in 55- to 64-year-
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old men due to phthalate exposure was identified, with
24 800 associated deaths annually. The obesity/diabetes
panel identified a 40–69% probability of phthalate ex-
posure causing 53 900 cases of obesity and 20 500 new-
onset cases of diabetes in older women annually. Pre-
natal BPA exposure was identified to have a 20–69%
probability of causing 42 400 new cases of childhood
obesity annually, with associated lifetime costs of €1.54
billion.
The most substantial costs were related to loss of IQ
and intellectual disability attributable to prenatal organo-
phosphate exposure; base case estimates identified €146
billion in attributable costs, whereas sensitivity analyses
suggested that costs might actually range from €46.8 to
195 billion annually. Phthalate-attributable adult obesity
was the second largest driver of costs, at €15.6 billion per
year. The total costs of all conditions probably attribut-
able to EDCs were €191 billion, with sensitivity analyses
suggesting costs ranging from €81.3 to 269 billion
annually.
Accounting for probability of causation, the base case
Monte Carlo simulation using the midpoint of each range
for probability of causation produced costs between €2.5
billion and 239 billion annually across the 1000 simula-
tions (median, €157 billion; Figure 1). Using the 2010 EU
purchasing-power-parity corrected GDP estimate of
€127.9 billion (59), the estimated costs comprise 1.23%
of GDP. There is a 5% probability that costs of EDC
exposures are less than €21.3 billion annually, a 90%
probability that costs are at least €32.0 billion, a 75%
probability that costs are at least €65.6 billion/y, a
25%probabilityof costs at least€194billion/y, anda10%
probability of costs over €212 billion/y.
Notably, using the lowest end of the probability range
for each relationship in theMonte Carlo simulations pro-
duced a range of €44.0 million to 235 billion (median,
€109 billion) that differed modestly from the base case
probability inputs. There is a 5% probability that costs of
EDCexposures are less than€10.0billionannually, a90%
probability that costs are at least €15.8 billion, a 75%
probability that costs are at least €30.8 billion/y, a
25%probabilityof costs at least€181billion/y, anda10%
probability of costs over €204 billion/y. Applying the low-
est end of the probability range and assuming that all the
relationships are independent, multiplying each of the
probabilities for the exposure-outcome relationships sug-
gests a very high (99%  1–0.3  0.3  0.6  0.8 
0.6  0.6  0.8  0.6  0.6  0.6  0.6  0.8  0.8)
probability that EDCs contribute to disease in Europe.
Leaving aside the highly probable costs of developmental
neurotoxicity from organophosphate pesticide and bro-
minated flame retardants, there is still a substantial prob-
ability (98%) that one or more of the other exposure-
outcome relationships are causal. Using the highest end of
the probability ranges narrowed the range of costs more
substantially (€17.6 to 246 billion; median, €180 billion).
There was a 21.0% probability of costs under €100 bil-
lion, and a 31.5% probability of costs over €200 billion.
Table 4. Evaluations of Exposure-Outcome Relationships
Exposure Outcome
Strength of
Human
Evidence
Strength of
Toxicological
Evidence
Probability of
Causation, %
Base Estimate,
€
Low Estimate,
€
High Estimate,
€
PBDEs IQ loss and
intellectual
disability
Moderate-to-high Strong 70–100 9 587 571 420 1 577 449 522 22 356 864 892
Organophosphate
pesticides
IQ loss and
intellectual
disability
Moderate-to-high Strong 70–100 146 178 556 566 46 760 988 423 194 850 545 761
DDE Childhood obesity Moderate Moderate 40–69 24 610 041 24 610 041 86 448 264
DDE Adult diabetes Low Moderate 20–39 834 741 170 834 741 170 16 694 823 393
Di-2-ethylhexylphthalate Adult obesity Low Strong 40–69 15 610 612 091 15 610 612 091 15 610 612 091
Di-2-ethylhexylphthalate Adult diabetes Low Strong 40–69 606 944 344 606 944 344 606 944 344
BPA Childhood obesity Very low-to-low Strong 20–69 1 537 177 463 1 537 177 463 1 537 177 463
PBDEs Testicular cancer Very low-to-low Weak 0–19 847 975 932 313 179 835 847 975 932
PBDEs Cryptorchidism Low Strong 40–69 129 807 327 116 841 584 129 807 327
Benzyl and butyl
phthalates
Male infertility,
resulting in
increased
assisted
reproductive
technology
Low Strong 40–69 4 714 114 146 4 714 114 146 4 714 114 146
Phthalates Low T, resulting in
increased early
mortality
Low Strong 40–69 7 958 358 238 7 958 358 238 7 958 358 238
Multiple exposures ADHD Low-to-moderate Strong 20–69 1 743 332 686 1 212 298 027 2 861 405 410
Multiple exposures Autism Low Moderate 20–39 199 339 876 79 735 951 398 679 753
Abbreviation: ADHD, attention-deficit hyperactivity disorder.
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Discussion
The primary finding of this manuscript is that there is a
substantial probabilityof veryhighdisease costs across the
life span associated with EDC exposure in the EU. For
some perspective, the median €157 billion cost/y we iden-
tified is approximately one sixth the €798 billion Euro-
pean cost of brain disorders in 2010 (60) and 1.23% of
GDP. These costs will accrue annually insofar as expo-
sures that are harmful continue unabated. Thus, regula-
tory action to limit exposure to the most widely prevalent
and potentially hazardous EDCs is likely to produce sub-
stantial economic benefits. These economic benefits
should inform decision-making on measures to protect
public health.
Calculations of the health and economic benefits asso-
ciatedwith reducing exposure to environmental chemicals
haveproven extremely informative to regulatorydecision-
making. Estimates of the benefits associatedwith removal
of lead-based paint hazards informed funding of federal
lead hazard control grants in the early 2000s (61), and
measurement of the benefits associated with reduced pre-
natal methylmercury toxicity (62) informed formulation
of the global mercury treaty. Although analyses like these
are highly valuable, they have typically been limited to
associations where causation is certain. Decades of epide-
miological data typically are required before possible cau-
sation has been acknowledged and attributable disease
burden calculated (63, 64). Failure of the current ap-
proach in assessing the economic costs of environmental
health hazards is especially acute for EDCs, for which
longitudinal studies of early life exposures are only begin-
ning to be completed. The approach we have taken will
potentially transform decision-making in environmental
health by providing a new model for evaluating environ-
mental health risks and permitting a complete assessment
of the potential costs of failing to prevent chronic disease
through the use of safer alternatives to EDCs. It produces
substantial insights regarding the strength of the epidemi-
ological and toxicological data, placing them alongside
the cost of the disease as never done before. This approach
also documents data gaps in both the epidemiology and
toxicology of EDCs, which has only been documented
through systematic reviews.
We used an expert elicitation approach to estimate the
probability that EDCs contribute to disease anddisability.
Although the Global Burden of Disease project does rely
on expert opinion, it has focused on a small subset of
exposure-outcome relationships with the strongest causa-
tion. In preparation for this work, we considered the In-
ternational Agency for Research and Cancer (65) and
World Cancer Research Fund grading systems (66), but
these approaches could not be readily adapted to account
for the contribution by an endocrine disruptormechanism
for this project.
Figure 1. Economic costs of EDC exposures in EU, Monte Carlo analysis. The numbers on the x-axis denote cumulative probability across the
1000 simulations for base case probability of causation, as well as low and high bounds for probability of causation.
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Expert opinion is of course not a substitute for solid
epidemiological evidence regarding the relationships be-
tween EDCs and disease or for systematic toxicological
documentation regarding endocrine disruption as the
mechanism by which EDCs act to promote disease. Yet,
uncertainty is a reality across aspects of decision-making
in science and public policy, and we relied upon widely
accepted and usedmethods for accounting for uncertainty
(32). In the course of a 2-day workshop and associated
conference calls, the panels could not be comprehensive in
their examination of the panorama of EDCs and potential
effects. Although each accompanyingmanuscript endeav-
ors to call attention to the limited scope of the chemicals
and outcomes assessed, it should be emphasized that the
present work focused only on the conditions and expo-
sures with the strongest evidence for causation, within the
three disease areas for which the Steering Committee
judged the investment in assembling an expert panel to be
appropriate.
In addition to producing ranges of probability of cau-
sation based upon the strength of evidence, we also en-
deavored to incorporate the substantial uncertainty in
EDC-disease relationships using sensitivity analyses to
model impacts of key uncertainties on estimates of burden
of disease and costs that produced a wide range of poten-
tial costs associatedwithEDCs.The estimatespresented in
this report are uncertain, and the range of likely costs has
been expressed as allowed by the evidence available.
Clearly, more research would allow calculation of better
estimates, but it would take time and substantial invest-
ment. Given the current concerns about regulation of en-
docrine disruptors, the present report aims at providing
the best possible documentation for possible decision-
making at this time. Although the analysis was limited to
the EU, if similar exposures and effects are identified in the
UnitedStates andother areasof theworld, then theburden
of disease and costs attributable to EDCs elsewhere is
likely to be on the same order of magnitude. Additional
investment across the world in research to identify how
and which EDCs are harmful is also indicated.
Three additional issues should be considered when
evaluating our findings. First, the approach we took to
quantifying theprobabilityof costs fails to account for risk
aversion. Generally, societies value small probabilities of
costs (eg, 10% of US $1,000) more than the weighted
average (US $100  (10%  US $1,000)  (90%  US
$0)). A major driver for health insurance is that people
may value investment on behalf of preventing even a rare
but uncertain outcome more than the weighted-average
likelihood of the consequences of the outcome. Because
people generally prefer to pay more in such a scenario,
societies are described as risk-averse (67). We did not ac-
count for risk aversion in the present work. Indeed, the
societal value of the uncertain health effects analyzed here
may be much higher than our calculations. Second, cost-
of-illness approaches fail to capture the complete scope of
economic costs associated with illness (especially psycho-
logical and other indirect or intangible costs that are dif-
ficult to assess); thus, our cost-of-illness estimate of EDCs
must be considered an underestimate (68–71). Finally,
when considering the costs of safer alternatives, it is im-
portant to keep in mind that estimates of the cost of safer
alternatives produced by those who create environmental
toxicants may overestimate costs of prevention because
they do not account fully for ongoing technological inno-
vation that may reduce future costs of safer alternatives
(72). The costs of such innovations are often one-time
costs, whereas the benefits of prevention accumulate over
time, as has been documented with the annual economic
benefit of eradicating lead from gasoline (73).
Finally, the findings described here suggest potentially
large burdens of disease and associated costs in the devel-
oped world, insofar as exposures are similar. Future stud-
ies could extend and apply this approach to the United
States, where the National Health and Nutrition Exami-
nation Survey, among other studies, offers arguably more
comprehensive and national reference points for extrap-
olation. In the industrializing world, the attributable dis-
ease burden and costs could well be higher in a much
weaker regulatory framework (74). A major challenge to
documenting the scope of EDC-attributable disease in
these more vulnerable populations is the absence of bio-
marker or other exposure data to support similar esti-
mates. The World Health Organization and United
Nations Environment Programme can catalyze and coor-
dinate such efforts, which will require substantial re-
sources for its proper execution.
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